Drug Trial Radar · NCT06602193
Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)
Last checked: Nov 20, 2026Latest source record: May 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Mar 2027
Study completion Feb 28, 2028
Sponsor
- Lead sponsor
- Denali Therapeutics Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Biogen
- First posted
- Sep 19, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 30 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity.
Conditions
- Parkinson Disease
Interventions
BIIB122 225 mgDrug
Administered as specified in the treatment arm
BIIB122-Matching PlaceboOther
Administered as specified in the treatment arm
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind periodTime frame: 12 weeks
Locations
20 sites in 4 countries. Site status is shown where the registry gives one.
Cedars-Sinai Department of Neurology
Los Angeles, California
University of California San Francisco
San Francisco, California
Parkinson's Disease and Movement Disorders Center
Boca Raton, Florida
Beth Israel Deaconess Medical Center
Boston, Massachusetts
Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center
New York, New York
Evergreen Health Laboratory
Kirkland, Washington
Inland Northwest Research
Spokane, Washington
Technische Universität Dresden
Dresden, Germany
University of Lübeck
Lübeck, Germany
University Hospital Tübingen
Tübingen, Germany
Rabin Medical Center
Petah Tikva, Israel
Movement Disorders Institute, Sheba Medical Center
Ramat Gan, Israel
Tel Aviv Medical Center
Tel Aviv, Israel
Hospital Clinic de Barcelona
Barcelona, Spain
Hospital Universitari General de Catalunya
Barcelona, Spain
Hospital Universitari Vall d'Hebron
Barcelona, Spain
Hospital Universitario Donostia
Donostia / San Sebastian, Spain
Universitary Hospital La Princesa
Madrid, Spain
IDIVAL/University Hospital Marques de Valdecilla
Santander, Spain
Hospital Universitario Virgen del Rocio
Seville, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.